Schonfeld Strategic Advisors LLC Rigel Pharmaceuticals Inc Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $13,440 - $21,840	12,000 New	12,000 $15,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $32,096 - $48,552	-13,600 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$3.5 - $4.5 $1.19 Million - $1.53 Million	-339,733 Reduced 96.15%	13,600 $50,000
Q2 2021 Nov 16, 2021	SELL	$3.09 - $4.54 $1.09 Million - $1.6 Million	-353,333 Reduced 50.0%	353,333 $1.53 Million
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $2.18 Million - $3.21 Million	706,666 New	706,666 $3.07 Million
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $65,734 - $87,097	-32,867 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $68,363 - $110,433	32,867 New	32,867 $76,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $851,760 - $1.18 Million	-327,600 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $927,108 - $1.35 Million	327,600 New	327,600 $927,000
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $229,370 - $294,164	-64,794 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $209,284 - $278,614	64,794	64,794 $252,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.